Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study

October 26, 2010 By Bio-Medicine.Org

HAMILTON, N.J. and ROCKVILLE, Md., Oct. 26 /PRNewswire/ —
MedAvante, Inc., the leader in centralized expert evaluation of
central nervous system (CNS) disorders, and Rexahn Pharmaceuticals,
Inc. (NYSE Amex:
RNN
) a clinical stage pharmaceutical company developing and
commercializing potential best in class oncology and CNS
therapeutics, announced that Rexahn will use MedAvante ‘s Remote
Centralized Ratings™ in their randomized, double-blind,
placebo-controlled Phase 2b clinical study assessing the efficacy
of Serdaxin® in patients with major depressive disorder (MDD).
 MedAvante’s centralized ratings were chosen to reduce bias
and variability associated with CNS trials.

Rexahn is the latest in a growing number of pharmaceutical
companies deciding to use centralized raters, who are free of study
biases, for CNS trials. This approach has empirically demonstrated
the ability to reduce rater variability and the placebo effect.

Centralized assessments in other therapeutic areas, including
oncology, imaging and cardiovascular, are used to reduce bias and
minimize variability and have been described affirmatively in
regulatory guidance documents.  Now centralized calibrated
raters conducting real-time psychiatric assessments are achieving
the same benefits for sponsors of CNS studies.  

Rexahn’s Serdaxin is a well characterized chemical entity tested
for multiple CNS indications.  Data from a Phase 2a study in
MDD has shown that Serdaxin has the potential to improve symptoms
of depression, without the side effects commonly associated with
currently marketed antidepressants.

“As a company seeking to develop and deliver new treatments for
CNS disorders, it is vital that we design and conduct clinical
trials that maximize rater objectivity and standardization,” said
Rick Soni, President and Chief Operating Officer of Rexahn.

“

‘/>”/>

SOURCE

Related Articles Read More >

Carnegie Mellon University EEG-based BCI to control robotic hand
Non-invasive BCI enables robotic hand dexterity
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
How this device broke through the blood-brain barrier
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe